Abstract: A vehicle drive device and a control method therefor are provided. The vehicle drive device includes: a power source including a first rotating electrical machine; a second rotating electrical machine; a differential unit including three rotating elements to which a first output shaft, a second output shaft, and the second rotating electrical machine are connected; and an electronic control device. The electronic control device regeneratively controls the first rotating electrical machine and the second rotating electrical machine in such a manner that negative torque is applied to the first output shaft and the second output shaft, when performing regenerative control by the second rotating electrical machine in a drive mode in which torque from the power source is distributed to the first output shaft and the second output shaft by controlling torque of the second rotating electrical machine during deceleration of a vehicle.

Abstract: To provide a polymer having a high tumor/blood ratio. The present invention provides a polymer represented by the following formula (P1): wherein in the formula (P1), R0 represents any of a residue or a functional group derived from a cationic polymerization initiator; L represents a linker and L may not be present; n represents an integer of 1 or more; D represents a dye backbone of a dye having absorption in the near-infrared region.

Abstract: An object is to provide a polymer having a high tumor/blood ratio. The present invention provides a polymer represented by the following formula (P1): wherein in the formula (P1), R represents any of a residue derived from a polymerization initiator, or a functional group; A may not be present, and when present, A represents any of a low-molecular compound, a dye, a reporter molecule, a target-binding molecule, a polymer or D; L represents a linker and L may not be present; n1 represents an integer of 1 or more; and D represents a dye backbone of a dye having absorption in the near-infrared region.

Abstract: The present invention provides a molecular assembly which is less likely to accumulate in tissue other than cancer tissue, is highly safe for a living body, and can be prepared by a simple and safe method and whose particle size can be easily controlled. The present invention provides a molecular imaging system and a molecular probe useful for the system, and a drug delivery system and a molecular probe useful for the system. The present invention provides a method for preparing molecular assembly, by which the particle size of molecular assembly having a signal group or a drug can be arbitrarily controlled in order to allow the molecular assembly to effectively accumulate in cancer tissue by utilizing EPR effect.

Abstract: An object is to provide a polymer having a high tumor/blood ratio. The present invention provides a polymer represented by the following formula (P1): wherein in the formula (P1), R represents any of a residue derived from a polymerization initiator, or a functional group; A may not be present, and when present, A represents any of a low-molecular compound, a dye, a reporter molecule, a target-binding molecule, a polymer or D; L represents a linker and L may not be present; n1 represents an integer of 1 or more; and D represents a dye backbone of a dye having absorption in the near-infrared region.

Abstract: To provide a polymer having a high tumor/blood ratio. The present invention provides a polymer represented by the following formula (P1): wherein in the formula (P1), R0 represents any of a residue or a functional group derived from a cationic polymerization initiator; L represents a linker and L may not be present; n represents an integer of 1 or more; D represents a dye backbone of a dye having absorption in the near-infrared region.

Abstract: Provided is a polymeric micelle pharmaceutical preparation that can increase the ratio of contrast at tumor site to background contrast in a short period of time after administration of a lactosome and can suppress the ABC phenomenon so that the lactosome can be administered more than once within a short span. A branched-type amphiphilic block polymer comprising: a multi-branched hydrophilic block comprising sarcosine; and a hydrophobic block comprising polylactic acid. The branched-type amphiphilic block polymer, wherein the number of branches of the hydrophilic block is 3. A molecular assembly comprising the branched-type amphiphilic block polymer. The molecular assembly further comprising a linear type amphiphilic block polymer.

Abstract: The present invention provides a molecular assembly whose retention time in a target site is adjusted depending on the kind or purpose of a labeling agent or drug encapsulated therein, and a molecular assembly that can suppress the ABC phenomenon and that can be administered more than once within a short span.

Abstract: Provided is a polymeric micelle pharmaceutical preparation that can increase the ratio of contrast at tumor site to background contrast in a short period of time after administration of a lactosome and can suppress the ABC phenomenon so that the lactosome can be administered more than once within a short span. A branched-type amphiphilic block polymer comprising: a multi-branched hydrophilic block comprising sarcosine; and a hydrophobic block comprising polylactic acid. The branched-type amphiphilic block polymer, wherein the number of branches of the hydrophilic block is 3. A molecular assembly comprising the branched-type amphiphilic block polymer. The molecular assembly further comprising a linear type amphiphilic block polymer.

Abstract: Provided is a polymeric micelle pharmaceutical preparation that can increase the ratio of contrast at tumor site to background contrast in a short period of time after administration of a lactosome and can suppress the ABC phenomenon so that the lactosome can be administered more than once within a short span. A branched-type amphiphilic block polymer comprising: a multi-branched hydrophilic block comprising sarcosine; and a hydrophobic block comprising polylactic acid. The branched-type amphiphilic block polymer, wherein the number of branches of the hydrophilic block is 3. A molecular assembly comprising the branched-type amphiphilic block polymer. The molecular assembly further comprising a linear type amphiphilic block polymer.

Abstract: The present invention provides a molecular assembly whose retention time in a target site is adjusted depending on the kind or purpose of a labeling agent or drug encapsulated therein, and a molecular assembly that can suppress the ABC phenomenon and that can be administered more than once within a short span.

Abstract: Provided is a polymeric micelle pharmaceutical preparation that can increase the ratio of contrast at tumor site to background contrast in a short period of time after administration of a lactosome and can suppress the ABC phenomenon so that the lactosome can be administered more than once within a short span. A branched-type amphiphilic block polymer comprising: a multi-branched hydrophilic block comprising sarcosine; and a hydrophobic block comprising polylactic acid. The branched-type amphiphilic block polymer, wherein the number of branches of the hydrophilic block is 3. A molecular assembly comprising the branched-type amphiphilic block polymer. The molecular assembly further comprising a linear type amphiphilic block polymer.

Abstract: The present invention provides a molecular assembly which is less likely to accumulate in tissue other than cancer tissue, is highly safe for a living body, and can be prepared by a simple and safe method and whose particle size can be easily controlled. The present invention provides a molecular imaging system and a molecular probe useful for the system, and a drug delivery system and a molecular probe useful for the system. The present invention provides a method for preparing molecular assembly, by which the particle size of molecular assembly having a signal group or a drug can be arbitrarily controlled in order to allow the molecular assembly to effectively accumulate in cancer tissue by utilizing EPR effect.

Abstract: In the measurement of iodine value by the Wijs method, the measurement can be effected rapidly by using magnesium acetate or sodium acetate as a catalyst.When the catalyst is used, the reaction time of a sample with a Wijs solution is as short as about 3 minutes. The time required for the measurement is thus reduced remarkably.